Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group
- 15 February 2023
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (5) , e30251
Abstract
Background: Acute myeloid leukemia (AML) with megakaryocytic differentiation (AMkL) is a rare subtype of AML more common in children. Recent literature has identified multiple fusions associated with this type of leukemia.Methods: Morphology, cytogenetics, and genomic sequencing were assessed in patients from Children's Oncology Group trials AAML0531 and AAML1031 with central‐pathology review confirmed non‐Down syndrome AMkL. The 5‐year event‐free survival (EFS), overall survival (OS), and RR were evaluated in these AMkL subcategories.Results: A total of 107 cases of AMkL (5.5%) were included. Distinct fusions were identified in the majority: RBM15::MRTFA (20%), CBFA2T3::GLIS2 (16%), NUP98 (10%), KMT2A (7%), TEC::MLLT10 (2%), MECOM (1%), and FUS::ERG (1%); many of the remaining cases were classified as AMkL with (other) myelodysplasia‐related changes (MRC). Very few cases had AML‐associated somatic mutations. Cases with CBFA2T3::GLIS2 were enriched in trisomy 3 (p = .015) and the RAM phenotype, with associated high CD56 expression (p < .001). Cases with NUP98 fusions were enriched in trisomy 6 (p < .001), monosomy 13/del(13q) (p < .001), trisomy 21 (p = .026), and/or complex karyotypes (p = .026). While different 5‐year EFS and OS were observed in AMkL in each trial, in general, those with CBFA2T3::GLIS2 or KMT2A rearrangements had worse outcomes compared to other AMkL, while those with RBM15::MRTFA or classified as AMkl‐MRC fared better. AMkL with NUP98 fusions also had poor outcomes in the AAML1031 trial.Conclusion: Given the differences in outcomes, AMkL classification by fusions, cytogenetics, and morphology may be warranted to help in risk stratification and therapeutic options.Keywords
Funding Information
- St. Baldrick's Foundation
This publication has 46 references indexed in Scilit:
- Clinicopathological features of acute megakaryoblastic leukaemia: Relationship between fibrosis and platelet‐derived growth factorPathology International, 2013
- Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children’s Oncology Group Study POG 9421Leukemia, 2012
- Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupBlood, 2010
- Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupBlood, 2009
- Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification systemBlood, 2009
- The incidence and clinical significance of nucleophosmin mutations in childhood AMLBlood, 2007
- Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: Report from the Children's Oncology GroupPediatric Blood & Cancer, 2007
- Acute Megakaryoblastic Leukaemia: A National Clinical and Biological Study of 53 Adult and Childhood Cases by the Groupe Français d'Hématologie Cellulaire (GFHC)Leukemia & Lymphoma, 2003
- Acute Megakaryocytic Leukemia with the t(1;22)(p13;q13Leukemia & Lymphoma, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958